Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Rodina

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Assay and Drug Development Technologies|December 8, 2010
Design of a flexible cell-based assay for the evaluation of heat shock protein 70 expression modulatorsJames H Ahn, Wenjie Luo, Joungnam Kim, et al.
Journal of Medicinal Chemistry|February 20, 2014
Heat shock protein 70 inhibitors. 2. 2,5'-thiodipyrimidines, 5-(phenylthio)pyrimidines, 2-(pyridin-3-ylthio)pyrimidines, and 3-(phenylthio)pyridines as reversible binders to an allosteric site on heat shock protein 70Tony Taldone, Yanlong Kang, Hardik J Patel, et al.
Cold Spring Harbor Perspectives in Biology|April 3, 2019
A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and BeyondTony Taldone, Tai Wang, Anna Rodina, et al.
Blood|August 15, 2013
Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignanciesUtthara Nayar, Pin Lu, Rebecca L Goldstein, et al.
Cancer Cell|October 3, 2006
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulatorsHaley Hieronymus, Justin Lamb, Kenneth N Ross, et al.
Nature Chemical Biology|July 3, 2007
Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancerAnna Rodina, Maria Vilenchik, Kamalika Moulick, et al.
JCO Precision Oncology|December 7, 2020
Measuring Tumor Epichaperome Expression Using [<sup>124</sup>I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast CancerKomal L Jhaveri, Carlos H Dos Anjos, Tony Taldone, et al.
Molecular Cancer Therapeutics|June 17, 2017
Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt LymphomaLisa Giulino-Roth, Herman J van Besien, Tanner Dalton, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2009
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer modelsEloisi Caldas-Lopes, Leandro Cerchietti, James H Ahn, et al.
The Journal of Clinical Investigation|September 21, 2010
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansSachie Marubayashi, Priya Koppikar, Tony Taldone, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Assay and Drug Development Technologies|December 8, 2010
Design of a flexible cell-based assay for the evaluation of heat shock protein 70 expression modulatorsJames H Ahn, Wenjie Luo, Joungnam Kim, et al.
Journal of Medicinal Chemistry|February 20, 2014
Heat shock protein 70 inhibitors. 2. 2,5'-thiodipyrimidines, 5-(phenylthio)pyrimidines, 2-(pyridin-3-ylthio)pyrimidines, and 3-(phenylthio)pyridines as reversible binders to an allosteric site on heat shock protein 70Tony Taldone, Yanlong Kang, Hardik J Patel, et al.
Cold Spring Harbor Perspectives in Biology|April 3, 2019
A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and BeyondTony Taldone, Tai Wang, Anna Rodina, et al.
Blood|August 15, 2013
Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignanciesUtthara Nayar, Pin Lu, Rebecca L Goldstein, et al.
Cancer Cell|October 3, 2006
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulatorsHaley Hieronymus, Justin Lamb, Kenneth N Ross, et al.
Nature Chemical Biology|July 3, 2007
Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancerAnna Rodina, Maria Vilenchik, Kamalika Moulick, et al.
JCO Precision Oncology|December 7, 2020
Measuring Tumor Epichaperome Expression Using [<sup>124</sup>I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast CancerKomal L Jhaveri, Carlos H Dos Anjos, Tony Taldone, et al.
Molecular Cancer Therapeutics|June 17, 2017
Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt LymphomaLisa Giulino-Roth, Herman J van Besien, Tanner Dalton, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2009
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer modelsEloisi Caldas-Lopes, Leandro Cerchietti, James H Ahn, et al.
The Journal of Clinical Investigation|September 21, 2010
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansSachie Marubayashi, Priya Koppikar, Tony Taldone, et al.
Pageof 5